Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
25 hedge funds and large institutions have $470K invested in Bellicum Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
24% less funds holding
Funds holding: 33 → 25 (-8)
62% less capital invested
Capital invested by funds: $1.23M → $470K (-$758K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$3.47K |
| 2 |
Renaissance Technologies
New York
|
+$277 |
| 3 |
Morgan Stanley
New York
|
+$258 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$172 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$107K |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$41K |
| 3 |
HF
HRT Financial
New York
|
-$26K |
| 4 |
Millennium Management
New York
|
-$16K |
| 5 |
E
Ergoteles
New York
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
E
26
Ergoteles
New York
| – | -$13K | -18,105 | Closed |
|
|
SRC
27
Shufro Rose & Co
New York
| – | -$9.32K | -12,941 | Closed |
|
28
LPL Financial
San Diego,
California
| – | -$7.58K | -10,527 | Closed |
|
|
OCM
29
Orion Capital Management
Coronado,
California
| – | -$360 | -500 | Closed |
|
|
MCC
30
Money Concepts Capital
Palm Beach Gardens,
Florida
| – | -$190 | -264 | Closed |
|
BLCM Hedge Fund Activity: Q1 2023 in Review
25 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q1 2023, worth a combined $470K — down 62% from $1.23M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BLCM and 0 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was Jane Street, adding an estimated $3.47K. The largest seller was Vanguard Group, cutting an estimated $107K.
- 25 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q1 2023, down from 33 in Q4 2022.
- Funds reported $470K of Bellicum Pharmaceuticals, Inc. stock for Q1 2023, down 62% quarter-over-quarter.
- 0 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q1 2023 and 8 closed out, a net change of -8 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q1 2023 was Jane Street, an estimated $3.47K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q1 2023 was Vanguard Group, an estimated $107K sold.
Based on aggregated 13F filings for Q1 2023.